CD8A and neoplasm: We analyzed the area under the ROC curve (AUC) for CD40 expression in comparison with existing biomarker signatures, including tumor mutational burden (TMB), CD274 (PD-L1) and CD8 [14], as a tool for predicting response to immunotherapy (Fig. 2E).